RE:RE:RE:RE:MM’s Napkin Math The Vantive promotional material shows PMX as something they have exclusive distribution rights to in North America. The plan seems to have been for Baxter to transfer those rights to Vantive as part of the spin off. Maybe there were no immediate plans for a buyout of PMX. Now that there is the possibility of Baxter selling their Kidney Care asset that puts the PMX distribution rights up in the air. Baxter could conceivably keep them or could include them as part of the deal with the buyer. If the buyer has deep pockets maybe this makes an outright PMX buyout more likely.
hmmmmmmmm wrote: I'm curious how your math squares Vantive a company hoping to IPO at a 4.5Billion valuation, buying PMX -that you've priced at the low range of 5.13Billion (CA)?
And before you pivot to- Baxter is going to keep PMX for themselves- you might want to go back and look at all the Vantive promotional material which includes PMX as one of their assets. The materials were of course was created by Baxter for the spin off..